Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238217 | 0.90 | HTT (0.45) | SIGMAR1MEN1KMT2A | |
| SCHEMBL4244914 | 0.88 | MEN1 (0.42) | SIGMAR1MEN1KMT2AS1PR4S1PR1 | |
| SCHEMBL4237325 | 0.85 | SIGMAR1 (0.42) | SIGMAR1MEN1KMT2AS1PR5 | |
| SCHEMBL4240896 | 0.85 | SIGMAR1 (0.40) | SIGMAR1MEN1KMT2A | |
| SCHEMBL4242095 | 0.83 | LMNA (0.42) | SIGMAR1MEN1KMT2AS1PR1S1PR5 | |
| SCHEMBL4248187 | 0.82 | CCR5 (0.39) | — | |
| SCHEMBL4244057 | 0.80 | GRIN2B (0.36) | SIGMAR1MEN1KMT2AS1PR1KCNH2 | |
| SCHEMBL4245846 | 0.79 | MEN1 (0.40) | SIGMAR1MEN1KMT2AS1PR4S1PR1 | |
| SCHEMBL4241459 | 0.76 | ACHE (0.41) | SIGMAR1MEN1KMT2A | |
| SCHEMBL4237268 | 0.75 | MEN1 (0.42) | SIGMAR1MEN1KMT2AS1PR4S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | SIGMAR1 317/4885MEN1 1950/4885KMT2A 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.